Correlation Between Neurocrine Biosciences and ANI Pharmaceuticals

Can any of the company-specific risk be diversified away by investing in both Neurocrine Biosciences and ANI Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Neurocrine Biosciences and ANI Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Neurocrine Biosciences and ANI Pharmaceuticals, you can compare the effects of market volatilities on Neurocrine Biosciences and ANI Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Neurocrine Biosciences with a short position of ANI Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Neurocrine Biosciences and ANI Pharmaceuticals.

Diversification Opportunities for Neurocrine Biosciences and ANI Pharmaceuticals

-0.5

Correlation Coefficient

Neurocrine Biosciences  ANI Pharmaceuticals

Very good diversification

The 3 months correlation between Neurocrine and ANI is -0.5. Overlapping area represents the amount of risk that can be diversified away by holding Neurocrine Biosciences and ANI Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on ANI Pharmaceuticals and Neurocrine Biosciences is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Neurocrine Biosciences are associated (or correlated) with ANI Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of ANI Pharmaceuticals has no effect on the direction of Neurocrine Biosciences i.e., Neurocrine Biosciences and ANI Pharmaceuticals go up and down completely randomly.

Pair Corralation between Neurocrine Biosciences and ANI Pharmaceuticals

Given the investment horizon of 90 days Neurocrine Biosciences is expected to under-perform the ANI Pharmaceuticals. In addition to that, Neurocrine Biosciences is 1.12 times more volatile than ANI Pharmaceuticals. It trades about -0.09 of its total potential returns per unit of risk. ANI Pharmaceuticals is currently generating about 0.16 per unit of volatility. If you would invest  5,421  in ANI Pharmaceuticals on December 29, 2024 and sell it today you would earn a total of  1,415  from holding ANI Pharmaceuticals or generate 26.1% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Very Weak
Accuracy	100.0%
Values	Daily Returns

Neurocrine Biosciences  vs.  ANI Pharmaceuticals

Neurocrine Biosciences

Risk-Adjusted Performance

Very Weak

Over the last 90 days Neurocrine Biosciences has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of inconsistent performance in the last few months, the Stock's forward indicators remain fairly strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors.

ANI Pharmaceuticals

Risk-Adjusted Performance

Good

Compared to the overall equity markets, risk-adjusted returns on investments in ANI Pharmaceuticals are ranked lower than 12 (%) of all global equities and portfolios over the last 90 days. Even with relatively weak forward indicators, ANI Pharmaceuticals reported solid returns over the last few months and may actually be approaching a breakup point.

Pair Trading with Neurocrine Biosciences and ANI Pharmaceuticals

The main advantage of trading using opposite Neurocrine Biosciences and ANI Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Neurocrine Biosciences position performs unexpectedly, ANI Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in ANI Pharmaceuticals will offset losses from the drop in ANI Pharmaceuticals' long position.

The idea behind Neurocrine Biosciences and ANI Pharmaceuticals pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.